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Abstract 29 
Background: The anti-cancer potential of curcumin, a natural NFkβ inhibitor, has been 30 
reported extensively in breast, lung and other cancers.  In vitro and in vivo studies indicate that 31 
the therapeutic efficacy of curcumin is enhanced when formulated in a nanoparticulate carrier.  32 
However, the mechanism of action of curcumin at the molecular level in the hypoxic tumour 33 
micro-environment is not fully understood.  Hence, the aim of our study was to investigate the 34 
mechanism of action of curcumin formulated as nanoparticles in in vitro models of breast and 35 
lung cancer under a hypoxic micro-environment. 36 
Methods: Biodegradable poly (lactic-co-glycolic acid) PLGA nanoparticles (NP), loaded with 37 
curcumin (cur-PLGA-NP), were fabricated using a solvent evaporation technique to overcome 38 
solubility issues and to facilitate intracellular curcumin delivery.  Cytotoxicity of free curcumin 39 
and cur-PLGA-NP were evaluated in MDA-MB-231 and A549 cell lines using migration, 40 
invasion and colony formation assays.  All treatments were performed under a hypoxic micro-41 
environment and whole cell lysates from controls and test groups were used to determine the 42 
expression of HIF-1α and p65 levels using ELISA assays. 43 
Results: A ten-fold increase in solubility, three-fold increase in anti-cancer activity and a 44 
significant reduction in the levels of cellular HIF-1α and nuclear p65 (Rel A) were observed 45 
for cur-PLGA-NP, when compared to free curcumin. 46 
Conclusion: Our findings indicate that curcumin can effectively lower the elevated levels of 47 
HIF-1α and nuclear p65 (Rel A) in breast and lung cancer cells under a hypoxic tumour micro-48 
environment when delivered in nanoparticulate form.  This applied means of colloidal delivery 49 
could explain the improved anti-cancer efficacy of curcumin and has further potential 50 
applications in enhancing the activity of anti-cancer agents of low solubility. 51 
 52 
Keyword: nanotechnology, hypoxia, anti-cancer, curcumin, PLGA, intracellular delivery 53 
1. Introduction 54 
Curcumin is a well-known anti-cancer agent found in the rhizomes of the perennial herb 55 
Curcuma longa.  It has a long history of use in traditional medicine, covering a broad spectrum 56 
of conditions, such as cancer, diabetes, inflammation and Alzheimer’s disease1, 2.  The FDA 57 
has endorsed its status as a safe, home-based remedy.  In more structured and rigorous 58 
evaluations, comprising of more than 65 clinical trials, curcumin’s benefit in life-threatening 59 
diseases has been clearly demonstrated3.  In relation to inflammatory and cancerous disorders, 60 
its therapeutic action is attributed to its ability to module nuclear factor kappa-beta (NFkβ) 61 
transcriptional factor 4 5 and hypoxia inducible factor (HIF) 6 7.  Free curcumin and curcumin 62 
loaded into a nanoparticulate carrier have been reported to be of therapeutic value in almost all 63 
cancer types 8 9 10 11.  However, the exact molecular mechanism of action involved in the 64 
treatment of cancer under a pathophysiological, hypoxic, tumour micro-environment is not 65 
clearly understood.  It is known that over activation of NFkβ and HIF pathways is induced by 66 
an hypoxic micro-environment, which has been reported extensively in several tumour types 12 67 
13 14, 15.  This hypoxic micro-environment has been deemed responsible for metabolic adaption 68 
of cancerous cells, which result in tumour development, progression and reduced effectiveness 69 
of cancer therapeutics 14. 70 
Among all cancer types, breast cancer has been reported as the major cause of death 71 
among elderly women in Europe and the United States 16 17.  Paclitaxel, 5-flourouracil, 72 
cyclosporine and doxorubicin are the most commonly prescribed treatment options for breast 73 
and lung cancer 18, 19 & 20.  However, these conventional chemotherapeutics result in serious 74 
side-effects, such as constipation, nausea, alopecia, neuronal damage, bone marrow depletion 75 
and heart failure 21 22.  Of similar concern is mortality associated with lung cancer, which is 76 
reported as the major cause of cancer-related death in males in developing countries.  This 77 
outcome contributes approximately 18.2% to the total cancer death statistic 23.  Furthermore, 78 
tiredness, skin reactions, loss of appetite, neurotoxicity and hair loss are some of the general 79 
side effects associated with conventional therapeutics 24.  Patients suffering from breast and 80 
lung cancers usually have to undergo surgery and radiation-based treatments, in addition to 81 
chemotherapy.  Furthermore, these therapies are not site specific and cause extensive damage 82 
to healthy tissue 25.  In addition, these interventions interfere with the menopause and fertility 83 
26.  Hence, there is a pressing need to continue to develop safer and more effective alternatives 84 
for treating neoplastic disease. 85 
The therapeutic value of curcumin in the treatment of breast and lung cancer has been 86 
reported in in vitro, in vivo and clinical studies 27,28.  However, these findings highlight 87 
problematic solubility issues of curcumin, which result in low systemic bioavailability, poor 88 
pharmacokinetic profiles and sub-optimal delivery to target cells 29, 30.  Thus, the first objective 89 
of the present work was to use emulsion-based encapsulation methods to formulate a drug 90 
delivery system for curcumin with improved solubility and intra-cellular delivery properties.  91 
Nano-encapsulation of drugs in PLGA matrices has been reported to enhance therapeutic 92 
efficacy and targeting capabilities 31, protect from degradation 32 and improve aqueous 93 
solubility of poorly water-soluble drugs 33, 34.  Since curcumin is practically insoluble in water, 94 
it makes an ideal model drug for our current investigation 35.  Nano-encapsulation is also known 95 
to enhance cellular permeability and retention effects, which are proposed as mechanisms to 96 
target and enhance drug accumulation in solid tumour masses 36.  Since hypoxia plays a critical 97 
role in tumour development and progression, the second objective of our work was to 98 
investigate the molecular mechanism of action of free curcumin and nano-encapsulated 99 
curcumin.  Of particular interest was the effect on expression of two master transcriptional 100 
regulators HIF-1α and p65 (Rel A), which are known to be expressed in response to hypoxia 101 
and are positively associated with almost all cancer types 37, 38. 102 
We hypothesise that nano-encapsulation of curcumin will enhance its solubility and 103 
facilitate intracellular delivery.  These events will result in improved bioavailability and 104 
enhanced anti-cancer activity via modulation of the over-activated NFkβ and HIF pathways in 105 
lung and breast cancer cells seen under hypoxic condition.  We hypothesise further that there 106 
will be a resultant stabilisation of the tumour, and cessation of cell growth and spread.  In this 107 
study, the solvent evaporation method was employed, using sonication to homogenise the 108 
emulsion phases, and poly(vinyl alcohol) (PVA) to stabilise and control particle size 39.  109 
Optimisations of PLGA and PVA content were carried out to select optimum settings during 110 
the formulation of curcumin-loaded PLGA NP (cur-PLGA-NP).  The nanoparticle formulation 111 
exhibiting superior cellular uptake, retention and in vitro release was selected for further 112 
assessment of anti-cancer and anti-metastatic activity of curcumin in the highly metastatic 113 
breast (MDA-MB-231) and lung cancer (A549) cell lines. 114 
 115 
 116 
2. Materials and Methods 117 
 118 
2.1 Preparation of cur-PLGA NP 119 
Cur-PLGA-NP was formulated using an oil-in-water emulsion technique.  PLGA was 120 
dissolved in 2.0 ml chloroform, followed by addition of curcumin and sonication at 55 W for 121 
3 minutes (Branson Sonifier W-350, Danbury, CT, USA).  Once dissolution was complete, the 122 
solution was added to an aqueous solution of 1.5% PVA and sonicated again at 55 W for 3 123 
minutes to form the final o/w emulsion.  This was stirred overnight and then centrifuged at 124 
16584g for 30 minutes to assist the removal of residual solvents.  The nanospheres obtained 125 
were washed three times with deionised distilled water.  NP were lyophilised for 72 hours 126 
(FreeZone 4.5plus) and stored at 4 °C until further use 40.  Fluorescent NP were prepared by 127 
adding 1µg of Nile Red to PLGA/curcumin solution in ethanol. 40 128 
 129 
2.2 Physicochemical characterisation  130 
 131 
2.2.1 Particles size and zeta potential 132 
Particle size and distribution of cur-PLGA-NP were determined using dynamic light scattering 133 
(Zetasizer 5000, Malvern Instruments, Malvern, UK).  An aliquot of NP suspension (5 mg ml1), 134 
previously vortex, was diluted in ultrapure water and used to measure mean diameter.  135 
Electrophoretic mobility was used to measure the zeta potential of cur-PLGA-NP.  136 
Conductivity was adjusted using 0.001 M KCl.  The mean of three measurements was recorded 137 
41. 138 
 139 
2.2.2 Entrapment efficiency 140 
Entrapment efficiency was determined using an indirect method.  The concentration of non-141 
encapsulated curcumin in the supernatant was measured by absorption spectrophotometry at 142 
430 nm and compared to a standard plot 42.  The amount of curcumin encapsulated in NP was 143 
calculated from the difference between the initial amount of curcumin added and the non-144 
encapsulated curcumin remaining in the external aqueous phase after NP fabrication.  All 145 
measurements were recorded in triplicate and the mean of each sample was reported as the 146 




2.2.3 In vitro release study 151 
The release of curcumin from PLGA NP was determined in phosphate buffered saline (pH 7.4, 152 
containing 0.1% w/v Tween-80) as a release phase.  Briefly, cur-PLGA-NP (5.0 mg) were 153 
suspended in a dialysis compartment (MW cut-off 17 kD) and suspended in 1.0 ml PBS 154 
solution.  The sample pouches were incubated at 37 °C in a reciprocal shaking water bath (100 155 
rpm) 35.  Samples were taken during a period of 168 hours at predetermined time intervals. 156 
 157 
2.2.4 Determination of water solubility 158 
Apparent water solubility of curcumin, formulated as cur-PLGA-NP, was compared with an 159 
equivalent amount of free curcumin dispersed in distilled water.  The mixtures were stirred for 160 
24 hours.  These solutions were then centrifuged at 13,450g for 10 minutes and the absorbance 161 
of the supernatant measured using ultraviolet spectroscopy 43. 162 
 163 
2..2.5 Particle surface morphology 164 
Surface morphology was characterised using scanning electron microscopy (FEI Quanta 400 165 
FEG, FEI).  A sample of NP was mounted on carbon tape and sputter-coated with gold under 166 
vacuum in an argon atmosphere prior to imaging. 167 
 168 
2.3 Culture materials 169 
MDA-MB-231 cells (a metastatic breast cancer cell line) and A549 cells (a metastatic lung 170 
cancer cell line) were maintained as monolayer cultures in Dulbecco’s modified Eagle’s 171 
medium–high glucose (DMEM-Hi) medium (Gibco BRL, Grand Island, NY) supplemented 172 
with 10% foetal bovine serum (Gibco BRL, Grand Island, NY) and 1% penicillin–streptomycin 173 
(Gibco BRL, Grand Island, NY) at 37 °C in a humidified atmosphere (5% CO2). 174 
Different concentration of free curcumin and cur-PLGA-NP were dissolved in 20 µl of 175 
DMSO.  This solution was then diluted to 2 ml with Optimem® media. 176 
 177 
2.4 Co-localisation of cur-PLGA-NP 178 
Cellular uptake of cur-PLGA-NP was investigated by seeding 1.0×105 MDA-MB-231 and 179 
A549 cells on chamber slides in 6-well plates.  Cells were incubated with Nile Red-labelled 180 
cur-PLGA-NP for 24 hours and fixed with 4% paraformaldehyde for 15 minutes.  The nucleus 181 
was stained with 5.0 µg DAPI in 1.0 ml normal media and incubated for 15 minutes 44.  The 182 
fluorescence images were obtained using phase contrast microscopy (Nicole Eclipse E400 183 
Florescence Microscope, Nikon Y-FL, Japan). 184 
 185 
2.5 Migration assay 186 
A migration assay was performed using an in vitro scratch assay, as previously described 45.  187 
To quantify the results captured from photographic images, ImageJ® software was used to 188 
measure the width of the scratch at three different points.  The degree of closure over 24 hours 189 
was calculated using the difference of the scratch width between 0 and 24 hours for each 190 
treatment concentration.  The degree of scratch closure for each treatment was compared to the 191 
degree of closure in the control cells. 192 
 193 
2.6 In vitro cytotoxicity 194 
Cytotoxicity assays were performed, as previously reported by Kumar et al. 46 with minor 195 
modifications.  MDA-MB-231 and A549 cells (5.0 x 104 cells per well in 500 µl media) were 196 
seeded in 24-well plates.  The following day, cells were treated with different concentrations 197 
of free curcumin or cur-PLGA-NP suspended in Optimem® media.  Medium containing 198 
equivalent amounts of blank PLGA NP was used as the control.  The cytotoxic effect of 10, 20 199 
and 30 µM of the free curcumin or cur-PLGA-NP was determined every 24 hours using MTT 200 
assay to assess the viability of cancer cells.  The treated cells were washed with 500 µL PBS, 201 
then 500 µL of 15% MTT dye solution in complete media was added to each well.  The plates 202 
were incubated at 37°C and 5% CO2 for an additional 3 hours.  The supernatant was discarded 203 
and formazan crystals solubilised by adding 500 µL of DMSO.  The absorption was measured 204 
at 570 nm (reference wavelength 630 nm) in a microplate reader (Fluostar Omega, BMG Lab 205 
Tech GMBH, Germany).  The anti-proliferative effect of different doses of free curcumin or 206 
cur-PLGA-NP treatments was calculated as a percentage of cell growth with respect to the 207 
blank NP controls.  The absorbance of the untreated cells was set at 100%.  All the experiments 208 
were repeated three times. 209 
 210 
2.7 Invasion assay 211 
The effect of curcumin treatment on invasion of MDA-MB231 and A549 cells was performed 212 
as previously described 47. Transwell® inserts of 8 µm pore size were inserted in 12-well plates 213 
(BD Bioscience, San Jose, CA). 135 µl solutions of Matrigel and water (1:1) was placed on 214 
these inserts. Cells (4x104) were seeded in a suspension of 200 µl of serum free media. 215 
Subsequently, 100 µl containing 10, 20 and 30 µM of the free curcumin or cur-PLGA-NP 216 
suspended in serum free media was added in the insert. The same volume of 100 µl containing 217 
equivalent amounts of blank PLGA NP was used as a control. 700 µl of DMEM media 218 
containing 10% FBS was added to each well as chemo-attractant. After 24 hours, the media in 219 
both chambers was removed and clean off any remaining cells or Matrigel® layer. The inserts 220 
were placed into another well containing 500 µl methanol for 10 minutes for fixation and left 221 
to dry. The membrane was cut and placed with the surface facing upwards in wells of a new 222 
12-well plate. Crystal Violet solution (250 µl) was added in the well to stain up the invaded 223 
cells. After drying the membrane 250 µl of 70% ethanol was added to membrane and shaken 224 
for 30 minutes. 200 µl was pipetted out from this 70% ethanol and absorbance was measured 225 
at 590 nm (Fluostar Omega, BMG Lab Tech GMBH, Germany). The effect of different doses 226 
of free curcumin or cur-PLGA-NP treatments was calculated as a percentage of cell invasions 227 
with respect to the blank NP controls. The absorbance of the untreated the absorbance of the 228 
untreated cells was set at 100%. All the experiments were repeated three times. 229 
 230 
2.8 Colony formation assay 231 
An aliquot of approximately 500 cells (MDA-MB-231 and A549) were seeded in 2.0 ml media 232 
in 6-well plates and allowed stand for 2 days to attach and initiate colony formation 35.  These 233 
cells were treated with different concentrations of 10, 20 and 30 µM of free curcumin or cur-234 
PLGA-NP suspended in Optimem® media over a period of 7 days.  The plates were washed 235 
twice with PBS, fixed in chilled methanol, stained with Crystal Violet, washed with water and 236 
air-dried.  The number of colonies was counted visually.  The % colony formation was 237 
calculated by comparing the number of colonies formed in the test experiment to the number 238 
of colonies formed using blank PLGA NP. 239 
 240 
2.9 Quantification of HIF-1a and p65 levels 241 
MDA-MB-231 and A549 cells (treated for 24 hours with 10% oxygen) were treated with (i) 242 
free curcumin, (ii) cur-PLGA-NP and (iii) blank PLGA-NP.  Whole cell lysates were prepared 243 
and assayed for HIF-1a and p65 levels using Invitrogen HIF1A Human ELISA Kit (EHIF1A) 244 
and NFkβ p65 (Total) Human ELISA Kit (KHO0371) and used according to the 245 
manufacturer’s instructions at 450 nm, using a BioTek optical plate reader.  Optical density 246 
was converted to concentration (pg ml-1) using the standard calibration curve provided in the 247 
manufacture's protocol. 248 
 249 
2.10 Statistical analysis 250 
Each experiment was performed in triplicate.  Statistical analysis was performed using 251 
GraphPad Prism v5.0.  Results are presented as mean +/- standard error of the mean (SEM).  252 
Particle size, zeta potential, entrapment efficiency and values of in vitro release profiles were 253 
treated statistically using one-way analysis of variance (ANOVA).  P < 0.05 was considered 254 
statistically significant. 255 
 256 
 257 
3. Results and Discussion 258 
 259 
3.1 Effect of PLGA concentration 260 
Three batches nanoparticles (F1, F2 and F3) were formulated with a different amount of PLGA 261 
and an equal amount of curcumin, as shown in the table I.  The effect of increasing the quantity 262 
of polymer for the formulation of cur-PLGA-NP on its physiochemical properties is shown in 263 
Figure 1.  It was found that particle size increased significantly from 265 nm to 606 nm (P-264 
value < 0.0001) as the quantity of PLGA increased (Figure 1A).  This increase in size is due to 265 
increase in the viscosity of polymer solution and formation of larger disperses droplets 41, 48.  It 266 
was also observed that increasing the amount of polymer increased the zeta potential 267 
significantly from –13.7 mV (F1) to -3.1 mV (Figure 1B; P-value < 0.01).  This could be due 268 
to the accumulation of ionised carboxylic groups on the nanoparticles as result of an increase 269 
of PLGA.  Entrapment efficiency increased significantly, as the ratio of PLGA increased 270 
(Figure 1C).  Similar results were reported by Derman et al. 49.  It is proposed that the increase 271 
in PLGA in the organic phase increases the viscosity and reduces diffusivity to the water phase 272 
41, 50.  The data in Figure 1D show the release profile for curcumin from three different 273 
formulations.  All three formulations show a similar release trend with a burst effect after 24 274 
hours. 275 
 276 
3.2 Solubility of cur-PLGA-NP and free curcumin  277 
The apparent water solubility of curcumin in both free and nano-encapsulated form was 278 
determined by UV spectroscopy at 430 nm.  The vials in Figure 2A give a visual representation 279 
of the enhanced solubility of curcumin when formulated as cur-PLGA-NP when compared to 280 
free curcumin in water.  It is evident that cur-PLGA-NP produce a uniform dispersion, whereas 281 
free curcumin was sparingly soluble in water.  The solubility of free curcumin was found to be 282 
0.935 µmol, whereas ostensible solubility of cur-PLGA-NP (curcumin encapsulated in NP) 283 
was 9.535 µmol.  These results indicate an approximately ten-fold increase in aqueous 284 
solubility of cur-PLGA-NP as compared to free curcumin. 285 
 286 
3.3 Scanning Electron Microscopy 287 
Figure 3 shows SEM images of F1, F2, and F3 formulated with 30 mg, 60 mg and 90 mg of 288 
polymer with equal amounts of curcumin and PVA.  F1 exhibits a monodisperse appearance, 289 
with the smallest particle size.  SEM images of cur-PLGA-NP suggest that an increase in the 290 
polymer (PLGA) concentration not only leads to an increase in particle size but also results in 291 
non-spherical particles.  Thus, F1 batch was selected for in vitro analysis based on its smaller 292 
particle size. 293 
 294 
3.4 Cellular uptake 295 
The nuclei of MDA-MB-231 and A549 cells were stained with DAPI and Nile Red-tagged cur-296 
PLGA-NP were observed under fluorescent microscopy.  Cellular uptake of cur-PLGA-NP 297 
labelled with Nile Red, in MDA-MB-231 and A549 cells, were visualised by overlaying images 298 
obtained by fluorescent microscopy.  Nile Red encapsulated cur-PLGA-NP can be seen within 299 
the MDA-MB-231 and A549 cells as depicted in the Figure 4A and 4B.  The result indicates 300 
that formulation F1 NP may be taken up by the cells.  However, since the cell boundaries are 301 
not seen clearly this result cannot be confirmed. 302 
 303 
3.5 Migration assay 304 
Migration of cancer cells from the primary tumour site to other sites is a predominant feature 305 
of metastatic breast and lung cancer cells 51.  Therefore, in this work, a scratch assay was 306 
conducted on both cell lines to investigate doses response of free curcumin and cur-PLGA-NP 307 
on the migration of MDA-MB-231 (Figure 5A) and A549 (Figure 5B) cells.  Figure 5 shows 308 
the graphical quantification of the degree of closure in breast and lung cancer cell lines relative 309 
to the blank NP controls.  Treatment with free curcumin resulted in higher degree of wound 310 
closure for all concentrations in both cell lines. Treatment with cur-PLGA-NP resulted in  311 
significant  reduction in the degree of wound closure compared to the free curcumin after 72 312 
hours at similar concentrations of curcumin (Figure 5A and B).  These results demonstrated 313 
that cur-PLGA-NP have the superior anti-migration capability when compared to free 314 
curcumin. 315 
 316 
3.6 Invasion assay 317 
An invasion assay was conducted to investigate the effect of free curcumin and cur-PLGA-NP 318 
on the invasion capability of MDA-MB-231 (Figure 6A) and A549 (Figure 6B) cells.  319 
Dissemination of tumour cells from the primary site to distant locations starts with cell 320 
detachment followed by the local invasion of the normal tissues adjacent to the tumour which 321 
then can infiltration through the lymphatic drainage system 51.  Treatment with cur-PLGA-NP 322 
resulted in a significant decrease in cell invasion compared to free curcumin for all 323 
concentrations in both cell lines as shown in Figure 6.  These results suggest that Cur-PLGA-324 
NP can significantly inhibit the invasion capability of invasive lung and breast cancer cells 325 
when compared to free curcumin.  This enhanced anti-invasive effect imparted to curcumin by 326 
nano-encapsulation is critical to inhibit metastasis of highly invasive breast and lung cancer 327 
cells. 328 
 329 
3.7 Colony formation assay 330 
Colony formation assay has been widely to study the long-term anti-cancer activity of 331 
curcumin35.  The number of colonies formed after 7 days was quantified for MDA-MB-231 332 
(Figure 7A) and A549 (Figure 7B) cells treated with blank PLGA-NP as control, along with 333 
three different concentrations of free curcumin and cur-PLGA-NP.  Treatment with cur-PLGA-334 
NP resulted in significantly lower numbers of colonies compared to free curcumin, as shown 335 
Figure 7A and B.  336 
 337 
3.8 Assessment of HIF-1a and p65 levels 338 
Having assessed the physical parameters, aqueous solubility, intracellular uptake and anti-339 
cancer potential of cur-PLGA-NP versus free curcumin, we need to investigate the molecular 340 
mechanism for improved anti-cancer potential of curcumin when formulated as PLGA 341 
nanoparticles.  Recent research indicates that metastatic human cancer tumours are hypoxic 342 
and these cells could have elevated levels HIF-1a and NFkβ/p65 (Rel A) which may result in 343 
tumour development and progression of cancer 52 53-56.  Hence, to investigate if curcumin 344 
treatment has an effect on these transcription factors, we used whole cell lysates from 345 
metastatic breast (MDA-MB-231) and lung (A549) cancer cells treated with blank NP, cur-346 
PLGA-NP and free curcumin under hypoxic condition (10% O2) to quantify the levels of HIF-347 
1a and p65 (Rel A) using ELISA assay.  The results from the ELISA assay indicated that free 348 
curcumin had no significant effect on the levels of HIF-1a and p65 (Rel A) when compared to 349 
blank NP.  However, there was a significant reduction in the levels of HIF-1a (Figure 8: Panel 350 
A) and p65 (Rel A) (Figure 8: Panel B) in both breast and lung cancer cells treated with cur-351 
PLGA-NP (Figure 8; (P< 0.001 – 0.01).  These findings indicate that curcumin can suppress 352 
the cellular levels of HIF-1a and p65 (Rel A) only when delivered using a colloidal carrier.  353 
Metastatic breast (MDA-MB-231) and lung (A549) cancer cells show basal levels of HIF-1a 354 
and NFkβ/p65 (Rel A) under normal (21%) atmospheric O2 level (Supplementary Figure 1).355 
4. Conclusions 
Curcumin has received considerable attention as a potent anti-cancer 57 and anti-inflammatory 
agent 5.  However, it is not currently used as a clinical medicine for treating inflammation or 
cancer.  Results from our work have demonstrated the effect of increasing amount of PLGA on 
particle size, zeta potential, entrapment efficiency and in vitro release.  These findings are in 
agreement with previously published data 58.  Figure 1 shows that increase in PLGA amount 
increases the particle size, zeta potential and entrapment efficiency significantly.  However, the 
percentage release decreased with increases in PLGA concentration in the nanoparticle 
formulation.  This may be due to increase in the viscosity of polymer solution.  We also 
observed a ten-fold increase in curcumin solubility when formulated as PLGA nanoparticles 
(Figure 2) this increased solubility can increase the bioavailability of curcumin and intra-
cellular delivery59.  SEM images from the batches F1, F2 and F3, as shown in Figure 3, 
demonstrated that increasse in PLGA amount not only leads to increases in particle size, but 
also distorts the spherical structure of the nanoparticles.  Our work indicates that curcumin 
uptake by cancer cells is achieved when it is formulated as PLGA nanoparticles (Figure 4).  
This evidence of cellular uptake of curcumin nanoparticles forms the basis of our further 
findings indicating reduced migration (Figure 5), and proliferation (Supplementary Figure 2) 
ability decreased invasion power (Figure 6), with reduction in colony formation (Figure 7) of 
the breast and lung cancer cells.  Similar findings related to the anti-cancer potential of 
curcumin and curcumin nanoparticles have been reported by several researchers 60-67.  However, 
there is no study to date reporting the action of curcumin and curcumin nanoparticles on 
elevated levels HIF-1a and p65 (Rel A) in breast and lung cancer cells under tumour hypoxic 
condition. 
The most important findings of our current work indicate that nano-encapsulation of 
curcumin is capable of downregulating the expression of HIF-1a and p65 (Rel A) levels in 
breast and lung cancer cells when exposed to hypoxia (10% O2) (Figure 8).  This finding 
suggests that the increased therapeutic value of the natural anti-cancer agent curcumin could 
be via suppression of over activated HIF and NFkβ pathways, which are predominately 
responsible for adaptation of hypoxic tumours resulting in the development and spread of 
cancer in our body.  Hence, the findings from our work conclude that nanotechnology-based 
drug delivery system could be an effective tool to enhance the anti-cancer activity of several 
natural and/or novel anti-cancer compounds, which are currently not in clinical use due to their 
low solubility and/or poor bioavailability.  Future work will involve functionalising these 
PLGA-NP using salic acid to selectively target cancer tumour cells in in-vivo models of lung 
and breast cancer. 
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Figure 1. Effect of polymer amount on particle size, zeta potential, encapsulation 
efficiency and in-vitro release  
The particle size of nanoparticles increases significantly as the polymer amount increases from 
30 mg to 90 mg (A). Zeta potential decreases significantly (p-value < 0.002) upon increasing 
the polymer amount from 30 mg to 90 mg (B). Entrapment efficiency increases with increase 
in PLGA amount (C). The release profile depicts initial burst release after 24 hours. 
Nanoparticles formulated using 60 mg PLGA shows the highest percentage release of curcumin 
(D). Values are mean ± SEM (n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001 compared with 
30 mg PLGA.  Δp < 0.05 and ΔΔΔp < 0.001 compared with 60 mg of PLGA. 
 
Figure 2. Water solubility of cur-PLGA-NP, free curcumin and UV-spectra of cur-
PLGA-NP and free curcumin.  
The vials in Figure A shows the solubility of cur-PLGA-NP and free curcumin respectively. 
The free curcumin precipitates and settles down whereas cur-PLGA-NP shows uniform 
dispersion throughout the vial.  Figure B shows the absorption spectra of cur-PLGA-NP and 
free curcumin. cur-PLGA-NP shows the greater area under the curve as compared to free 
curcumin in Figure B. 
 
Figure 3. Scanning Electron Microscopy of cur-PLGA-NP F1, F2, and F3 containing 30 
mg, 60 mg and 90 mg of PLGA polymer respectively.  
Scanning electron microscopic images of F1, F2 and F3 batches containing 30 mg, 60 mg and 
90 mg of PLGA demonstrate an increase in particle size. F1 has smaller and uniform particle 
size as compared to F2 and F3. SEM images confirm that increase in polymer amount leads to 
increase in particle size and distortion of particle shape. 
 Figure 4. Cellular Uptake of cur-PLGA-NP in MDA-MB231.   
Cellular localisation of Nile red-coated cur-PLGA-NP were observed in MDA-MB231 (A) and 




Figure 5. Effect of cur-PLGA-NP and free curcumin on the migration of MDA-MB231 
and A549 cell lines. 
The effect of cur-PLGA-NP and free curcumin on migration capacity of MDA-MB231 (A) and 
A549 (B) cell lines were evaluated. Cur-PLGA-NP shows significant reduction in migration 
capability of both cell lines as compared to free curcumin. Values are mean ± SEM with n=3.  
*P<0.05, **P<0.01, ***P<0.001 compared with control (blank NP). ΔP<0.05, ΔΔ P<0.01, 
ΔΔΔP<0.001 compared with the same dose of free curcumin. 
 
Figure 6. Effect of cur-PLGA-NP and free curcumin on invasion of MDA-MB231 and 
A549 cell lines. 
The effect of cur-PLGA-NP and free curcumin on invasion capability of MDA-MB231 (A) 
and A549 (B) cell lines was observed. Cur-PLGA-NP shows a significant reduction in invasion 
capability of both cell lines as compared to free curcumin. Values are mean ± SEM with n=3. 
*P<0.05, **P<0.01, ***P<0.001 compared with control (blank NP). ΔP<0.05, ΔΔ P<0.01, 
ΔΔΔP<0.001 compared with the same dose of free curcumin. 
 
Figure 7. Effect of cur-PLGA-NP and free curcumin on colony formation ability of MDA-
MB231 and A549 cell lines. 
Cur-PLGA-NP significantly reduces the colony formation ability of both MDA-MB231 (A) 
and A549 (B) cell lines. Cur-PLGA-NP shows a significant reduction in colony formation 
capability of both cell lines as compared to free curcumin. Values are mean ± SEM with n=3.  
*P<0.05, **P<0.01, ***P<0.001 compared with control (blank NP). ΔP<0.05, ΔΔ P<0.01, 
ΔΔΔP<0.001 compared with the same dose of free curcumin. 
 
Figure 8. Effect of cur-PLGA-NP and free curcumin on expression of cellular levels of 
HIF-1a and p65 (Rel A). 
 Cur-PLGA-NP significantly reduces the levels of HIF-1a (A) and p65 (Rel A) (B) in both 
MDA-MB231 and A549 cell lines. Values are mean ± SEM with n=4. **P<0.01, ***P<0.001 
compared with blank NP. ΔΔ P<0.01, ΔΔΔP<0.001 compared with the same dose of free 
curcumin treatment for 24 hours. 
 
Supplementary Figure 1. The level of HIF-1α and p65 in MDA-MB-231 and A549 at 
normal atmospheric (21%) O2 level. 
 
Supplementary Figure 2. Cytotoxicity of cur-PLGA-NP and raw curcumin in MDA-
MB231 and A549 cell lines   
 Cytotoxicity was performed on MDA-MB231 (A) and A549 (B) cell lines. 40×104 cells were 
seeded on 24-well plates and transfected with 10µM, 20µM and 30µM of raw curcumin and 
cur-PLGA-NP. The absorbance was measured after 24 hours, 48 hours, 72 hours and 96 hours. 
It is evident from the figures that cur-PLGA-NP have higher cellular viability and less 
cytotoxicity as compare to raw curcumin. Values are mean ± SEM (n = 3). 
 
 













































































































 Table 1: Process variables for curcumin loaded NPs and corresponding identifiers. 
Formulation code Amount of drug (mg)  Amount of polymer (mg)   
F1 20 30 
F2 20 60 
F3 20 90 
 
 
